# Study of Pembrolizumab With Bendamustine in Hodgkin Lymphoma

> **NCT04510636** · PHASE2 · RECRUITING · sponsor: **University Health Network, Toronto** · enrollment: 37 (estimated)

## Conditions studied

- Classical Hodgkin Lymphoma
- Relapsed Cancer
- Refractory Cancer

## Interventions

- **DRUG:** Pembrolizumab
- **DRUG:** Bendamustine Hydrochloride

## Key facts

- **NCT ID:** NCT04510636
- **Lead sponsor:** University Health Network, Toronto
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2021-12-20
- **Primary completion:** 2026-06-01
- **Final completion:** 2026-06-01
- **Target enrollment:** 37 (ESTIMATED)
- **Last updated:** 2024-03-22


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04510636

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04510636, "Study of Pembrolizumab With Bendamustine in Hodgkin Lymphoma". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT04510636. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*